BETAMETHASONE + SALICYLIC ACID

Adults:

Once to twice daily. In most cases a thin film should be applied to cover the affected area twice daily. For some patients adequate maintenance therapy may be achieved with less frequent application. It is recommended that betamethasone dipropionate + salicylic acid is prescribed for two weeks, and that treatment is reviewed at that time.

The maximum weekly dose should not exceed 60 g. Paediatric population Dosage in children should be limited to 5 days.

This medicine is generally well tolerated and side effects are rare. Continuous application without interruption may result in local atrophy of the skin, striae and superficial vascular dilation, particularly on the face. Adverse reactions that have been reported with the use of topical corticosteroids include: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis and allergic contact dermatitis.

The following may occur more frequently with the use of occlusive dressings: maceration of the skin, secondary infection, skin atrophy, striae and miliaria. 4) has been reported with corticosteroid use (frequency not known). 4). In addition, prolonged use of salicylic acid preparations may cause dermatitis.

Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

The label will state strong steroid. Occlusion must not be used, since under these circumstances the keratolytic action of salicylic acid may lead to enhanced absorption of the steroid. Local and systemic toxicity is common, especially following long continuous use on large areas of damaged skin, in flexures or with polythene occlusion.

If used in children or on the face courses should be limited to 5 days. Long term continuous therapy should be avoided in all patients irrespective of age. Topical corticosteroids may be hazardous in psoriasis for a number of reasons, including rebound relapses following development of tolerance, risk of generalised pustular psoriasis and local systemic toxicity due to impaired barrier function of the skin.

Careful patient supervision is important. It is dangerous if this product come into contact with the eyes. Avoid contact with the eyes and mucous membranes. The systemic absorption of betamethasone dipropionate and salicylic acid may be increased if extensive body surface areas or skin folds are treated for prolonged periods or with excessive amounts of steroids.

Suitable precautions should be taken in these circumstances, particularly with infants and children. If irritation or sensitisation develops with the use of this medicine, treatment should be discontinued. Any side effects that are reported following systemic use of corticosteroids, including adrenal suppression, may also occur with topical corticosteroids, especially in infants and children.

If excessive dryness or increased skin irritation develops, discontinue use of this preparation. Visual disturbance may be reported with systemic and topical (including, intranasal, inhaled and intraocular) corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes of visual disturbances which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.

Rosacea, acne, perioral dermatitis, perianal and genital pruritus. Hypersensitivity to any of the ingredients of the this medicine contraindicates its use as does tuberculous and most viral lesions of the skin, particularly herpes simplex, vacinia, varicella.

Betamethasone dipropionate + salicylic acid should not be used in napkin eruptions, fungal or bacterial skin infections without suitable concomitant anti-infective therapy.